Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:

IMI pushes stakeholders to GETREAL in new €16m 'real clinical data' project

This article was originally published in Scrip

Executive Summary

The Innovative Medicines Initiative (IMI) has launched a new €16.3m funded project called GETREAL which will work towards incorporating real-life clinical data into drug development. The goal is to help health technology assessment (HTA) bodies decide how best to grant patients access to new treatments, and through this assist pharmaceutical companies in making better decisions during drug development.

Table

View full table

Related Companies

Tags:
Latest Headlines

Japan Results Roundup: Weak Yen Provides A Boost But Some Sales Challenges Emerge

Deal Watch: Bristol Adds To Vaccines ‘Repertoire,’ Takes ‘Scenic’ View Of Cellular Pathways

Navigating A Transition Year: Five Takeaways From Pfizer’s Q1 Call

Astellas Stakes Claim In CAR-Ts For Solid Tumors With Poseida Deal

See All
UsernamePublicRestriction

Register

SC024710

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By